Antibody Information

General Information of This Antibody
Antibody ID
ANI0WBBSI
Antibody Name
HcHAb18
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Basigin (BSG)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HcHAb18-DM1 [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 8 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 23.23% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (1 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 23.23% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (2 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 38.63% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (4 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 56.95% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (8 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 89.22% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (16 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 94.2% (Day 29) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (30 mg/kg, i.v. injection weekly in a total 4 doses) induces efficient tumor cell killing in cell line-derived models of NCI-H226 cells with CD147 expression with high expression.
In Vivo Model NCI-H226 CDX model
In Vitro Model Pleural epithelioid mesothelioma NCI-H226 cells CVCL_1544
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 95.84% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (32 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 97.40% (Day 14) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (18 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of NCI-H460 cells with CD147 expression with high expression.
In Vivo Model NCI-H460 CDX model
In Vitro Model Lung large cell carcinoma NCI-H460 cells CVCL_0459
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.46 ug/mL
Positive CD147 expression (CD147 +++/++)
Method Description
In vitro efficacy of HcHAb18-DM1 versus HcHAb18 and IgG1-DM1 on six cell lines treated for 72 h.
In Vitro Model Pleural epithelioid mesothelioma NCI-H226 cells CVCL_1544
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.77 ug/mL
Positive CD147 expression (CD147 +++/++)
Method Description
In vitro efficacy of HcHAb18-DM1 versus HcHAb18 and IgG1-DM1 on six cell lines treated for 72 h.
In Vitro Model Lung large cell carcinoma NCI-H460 cells CVCL_0459
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.96 ug/mL
Positive CD147 expression (CD147 +++/++)
Method Description
In vitro efficacy of HcHAb18-DM1 versus HcHAb18 and IgG1-DM1 on six cell lines treated for 72 h.
In Vitro Model Lung squamous cell carcinoma NCI-H520 cells CVCL_1566
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
18.26 ug/mL
Positive CD147 expression (CD147 +++/++)
Method Description
In vitro efficacy of HcHAb18-DM1 versus HcHAb18 and IgG1-DM1 on six cell lines treated for 72 h.
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
References
Ref 1 A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer. Biochem Biophys Res Commun. 2019 Jun 11;513(4):1083-1091. doi: 10.1016/j.bbrc.2019.04.046. Epub 2019 Apr 19.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.